$NEPH
NEPHROS INC Stock $neph

$neph Overview Financials Valuation SEC Filings Company Website

2014 Q4 Form 10-K Financial Statement

#000114420415022858 Filed on April 15, 2015

Income Statement

Concept	2014 Q4	2014 Q3	2014 Q2
Revenue	$340.0K	$491.0K	$441.0K
YoY Change	47.83%	17.46%	-23.3%
Cost Of Revenue	$130.0K	$175.0K	$142.0K
YoY Change	-55.17%	-7.41%	-37.17%
Gross Profit	$220.0K	$316.0K	$299.0K
YoY Change	-466.67%	37.99%	-14.33%
Gross Profit Margin	64.71%	64.36%	67.8%
Selling, General & Admin	$690.0K	$765.0K	$700.0K
YoY Change	-11.54%	32.35%	6.06%
% of Gross Profit	313.64%	242.09%	234.11%
Research & Development	$260.0K	$178.0K	$180.0K
YoY Change	44.44%	-12.75%	-30.5%
% of Gross Profit	118.18%	56.33%	60.2%
Depreciation & Amortization	$0.00	$0.00	$120.0K
YoY Change			1100.0%
% of Gross Profit	0.0%	0.0%	40.13%
Operating Expenses	$1.000M	$997.0K	$935.0K
YoY Change	-0.99%	19.12%	-4.3%
Operating Profit	-$780.0K	-$681.0K	-$636.0K
YoY Change	-27.1%	12.01%	1.27%
Interest Expense	-$4.480M	$65.00K	$17.00K
YoY Change	-190.87%	1200.0%	-29.17%
% of Operating Profit
Other Income/Expense, Net	$20.00K	$41.00K	-$1.000K
YoY Change	-300.0%	4000.0%	-94.74%
Pretax Income	-$5.250M	$2.720M	-$5.340M
YoY Change	-236.36%	-545.9%	697.01%
Income Tax
% Of Pretax Income
Net Earnings	-$5.250M	$2.723M	-$5.339M
YoY Change	-236.36%	-213.08%	317.44%
Net Earnings / Revenue	-1544.12%	554.58%	-1210.66%
Basic Earnings Per Share		$0.11	-$0.21
Diluted Earnings Per Share	-$1.817M	-$0.02	-$1.907M
COMMON SHARES
Basic Shares Outstanding	25.26M shares	25.24M shares	25.17M shares
Diluted Shares Outstanding		33.49M shares	25.17M shares

Balance Sheet

Concept	2014 Q4	2014 Q3	2014 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.280M	$1.050M	$230.0K
YoY Change	120.69%	517.65%	-23.33%
Cash & Equivalents	$1.280M	$1.050M	$230.0K
Short-Term Investments
Other Short-Term Assets	$104.0K	$30.00K	$59.00K
YoY Change	-16.8%	-18.92%	-15.71%
Inventory	$186.0K	$108.0K	$163.0K
Prepaid Expenses
Receivables	$110.0K	$180.0K	$110.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$1.684M	$1.367M	$560.0K
YoY Change	70.45%	127.83%	-35.63%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.000K	$1.000K	$3.000K
YoY Change	-85.71%	-88.89%	-75.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.684M	$1.737M	$1.789M
YoY Change	-11.09%	-10.79%	-10.55%
Total Long-Term Assets	$1.685M	$1.738M	$1.792M
YoY Change	-11.36%	-11.15%	-10.93%
TOTAL ASSETS
Total Short-Term Assets	$1.684M	$1.367M	$560.0K
Total Long-Term Assets	$1.685M	$1.738M	$1.792M
Total Assets	$3.369M	$3.105M	$2.352M
YoY Change	16.61%	21.48%	-18.39%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$835.0K	$910.0K	$1.030M
YoY Change	-22.18%	-14.55%	31.04%
Accrued Expenses	$342.0K	$300.0K	$233.0K
YoY Change	-6.3%	63.93%	16.5%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$1.600M	$0.00
YoY Change	-100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$1.247M	$3.057M	$1.684M
YoY Change	-64.36%	56.77%	-0.3%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$7.800M	$430.0K	$450.0K
YoY Change	150.8%	138.89%	28.57%
Total Long-Term Liabilities	$7.800M	$430.0K	$450.0K
YoY Change	150.8%	138.89%	28.57%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.247M	$3.057M	$1.684M
Total Long-Term Liabilities	$7.800M	$430.0K	$450.0K
Total Liabilities	$9.050M	$3.490M	$2.136M
YoY Change	36.96%	64.16%	4.65%
SHAREHOLDERS EQUITY
Retained Earnings	-$114.2M	-$112.9M	-$115.6M
YoY Change	6.9%	2.39%	7.2%
Common Stock	$30.00K		$25.00K
YoY Change	66.67%		38.89%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$5.681M	-$390.0K	$216.0K
YoY Change
Total Liabilities & Shareholders Equity	$3.369M	$3.110M	$2.352M
YoY Change	16.61%	21.67%	-18.39%

Cashflow Statement

Concept	2014 Q4	2014 Q3	2014 Q2
OPERATING ACTIVITIES
Net Income	-$5.250M	$2.723M	-$5.339M
YoY Change	-236.36%	-213.08%	317.44%
Depreciation, Depletion And Amortization	$0.00	$0.00	$120.0K
YoY Change			1100.0%
Cash From Operating Activities	-$840.0K	-$790.0K	-$250.0K
YoY Change	-4.55%	464.29%	-84.66%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00
YoY Change
Cash From Investing Activities	$0.00	$0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$3.000M	$3.000M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.070M	1.610M	0.000
YoY Change	-17.69%	16000.0%	-100.0%
NET CHANGE
Cash From Operating Activities	-840.0K	-790.0K	-250.0K
Cash From Investing Activities	0.000	0.000
Cash From Financing Activities	1.070M	1.610M	0.000
Net Change In Cash	230.0K	820.0K	-250.0K
YoY Change	-45.24%	-730.77%	-600.0%
FREE CASH FLOW
Cash From Operating Activities	-$840.0K	-$790.0K	-$250.0K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2013Q4	us-gaap	Cash Cash	579000	USD
CY2013Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	122000	USD
CY2014Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	110000	USD
CY2013Q4	us-gaap	Inventory Net InventoryNet	162000	USD
CY2013Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	125000	USD
CY2014Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	104000	USD
CY2013Q4	us-gaap	Assets Current AssetsCurrent	988000	USD
CY2013Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7000	USD
CY2013Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1894000	USD
CY2013Q4	us-gaap	Assets Assets	2889000	USD
CY2013Q4	neph	Senior Secured Note Payable Net Of Discount SeniorSecuredNotePayableNetOfDiscount	1358000	USD
CY2013Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1073000	USD
CY2013Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	365000	USD
CY2013Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	703000	USD
CY2013Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3499000	USD
CY2013Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	0	USD
CY2014Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	417000	USD
CY2014Q4	us-gaap	Liabilities Liabilities	9050000	USD
CY2014Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2014Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2014Q4	us-gaap	Common Stock Value CommonStockValue	30000	USD
CY2013Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	102983000	USD
CY2014Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	108382000	USD
CY2014Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	72000	USD
CY2014Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-114165000	USD
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	-5681000	USD
CY2014Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	3369000	USD
CY2014Q4	us-gaap	Cash Cash	1284000	USD
CY2014Q4	us-gaap	Inventory Net InventoryNet	186000	USD
CY2014Q4	us-gaap	Assets Current AssetsCurrent	1684000	USD
CY2014Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1000	USD
CY2014Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1684000	USD
CY2014Q4	us-gaap	Assets Assets	3369000	USD
CY2014Q4	neph	Senior Secured Note Payable Net Of Discount SeniorSecuredNotePayableNetOfDiscount	0	USD
CY2014Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	835000	USD
CY2014Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	342000	USD
CY2014Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	70000	USD
CY2013Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.60
CY2014Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1247000	USD
CY2013Q4	us-gaap	Liabilities Liabilities	6608000	USD
CY2013Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2013Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2013Q4	us-gaap	Common Stock Value CommonStockValue	18000	USD
CY2013Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	74000	USD
CY2013Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-106794000	USD
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	-3719000	USD
CY2013Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2889000	USD
CY2014	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2870000	USD
CY2013	us-gaap	Operating Expenses OperatingExpenses	4159000	USD
CY2014	us-gaap	Operating Expenses OperatingExpenses	3868000	USD
CY2013Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2013Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2013Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2013Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2013Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	90000000	shares
CY2013Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	18082043	shares
CY2013Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	18082043	shares
CY2014Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	30391513	shares
CY2014	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	48000	USD
CY2014	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-12000	USD
CY2014	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	82000	USD
CY2014	neph	Increase Decrease In License And Supply Agreement Fee Payable IncreaseDecreaseInLicenseAndSupplyAgreementFeePayable	0	USD
CY2014	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-216000	USD
CY2014	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-2495000	USD
CY2014	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	USD
CY2014	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	0	USD
CY2013Q4	us-gaap	Inventory Gross InventoryGross	527000	USD
CY2014Q4	us-gaap	Inventory Gross InventoryGross	297000	USD
CY2014	us-gaap	Use Of Estimates UseOfEstimates	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><font style="FONT-SIZE: 10pt">Use of Estimates in the Preparation of Financial Statements</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities, at the date of the financial statements, and the reported amount of revenues and expenses, during the reporting period. Actual results could differ materially from those estimates. Included in these estimates are assumptions about the valuation of the warrant liability, the collection of accounts receivable, value of inventories, useful life of fixed assets and intangible assets, and assumptions used in determining stock compensation such as expected volatility and risk-free interest rate. Certain prior year amounts have been reclassified to conform to the current year presentation.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2014Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	2100000	USD
CY2014Q4	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	3000000	USD
CY2013Q4	neph	Senior Secured Note Debt Discount Amount SeniorSecuredNoteDebtDiscountAmount	142000	USD
CY2013Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2014Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2014Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2014Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2014Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2014Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2014Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	90000000	shares
CY2014Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	30391513	shares
CY2013Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	365000	USD
CY2014Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	111000	USD
CY2014Q3	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	177000	USD
CY2013Q4	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	195000	USD
CY2013	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	1029000	USD
CY2014	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	914000	USD
CY2013	us-gaap	Licenses Revenue LicensesRevenue	711000	USD
CY2014	us-gaap	Licenses Revenue LicensesRevenue	834000	USD
CY2013	us-gaap	Sales Revenue Net SalesRevenueNet	1740000	USD
CY2014	us-gaap	Sales Revenue Net SalesRevenueNet	1748000	USD
CY2013	us-gaap	Cost Of Goods Sold CostOfGoodsSold	898000	USD
CY2014	us-gaap	Cost Of Goods Sold CostOfGoodsSold	549000	USD
CY2013	us-gaap	Gross Profit GrossProfit	842000	USD
CY2014	us-gaap	Gross Profit GrossProfit	1199000	USD
CY2013	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	867000	USD
CY2014	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	781000	USD
CY2013	us-gaap	Depreciation And Amortization DepreciationAndAmortization	223000	USD
CY2014	us-gaap	Depreciation And Amortization DepreciationAndAmortization	217000	USD
CY2013	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	3069000	USD
CY2013	us-gaap	Operating Income Loss OperatingIncomeLoss	-3317000	USD
CY2014	us-gaap	Operating Income Loss OperatingIncomeLoss	-2669000	USD
CY2013	us-gaap	Interest Expense InterestExpense	351000	USD
CY2014	us-gaap	Interest Expense InterestExpense	483000	USD
CY2013	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	3000	USD
CY2014	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	USD
CY2013	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-33000	USD
CY2014	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	58000	USD
CY2014	us-gaap	Net Income Loss NetIncomeLoss	-7371000	USD
CY2013	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	1320000	USD
CY2013	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.08
CY2014	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.31
CY2013	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	15624999	shares
CY2014	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	23817184	shares
CY2014Q1	neph	Authorized Value Of Rights Offering AuthorizedValueOfRightsOffering	2800000	USD
CY2013Q1	neph	Authorized Value Of Rights Offering AuthorizedValueOfRightsOffering	3000000	USD
CY2014Q4	neph	Authorized Value Of Rights Offering AuthorizedValueOfRightsOffering	3000000	USD
CY2014Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight	0.28673	shares
CY2013Q2	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight	0.18776	shares
CY2014Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight	0.11901	shares
CY2014Q1	neph	Class Of Warrant Or Right Issued Gross Value Received ClassOfWarrantOrRightIssuedGrossValueReceived	2100000	USD
CY2013Q2	neph	Class Of Warrant Or Right Issued Gross Value Received ClassOfWarrantOrRightIssuedGrossValueReceived	3000000	USD
CY2014Q4	neph	Class Of Warrant Or Right Issued Gross Value Received ClassOfWarrantOrRightIssuedGrossValueReceived	3000000	USD
CY2014Q1	neph	Class Of Warrant Or Right Issued Net Value Received ClassOfWarrantOrRightIssuedNetValueReceived	581000	USD
CY2013Q2	neph	Class Of Warrant Or Right Issued Net Value Received ClassOfWarrantOrRightIssuedNetValueReceived	1400000	USD
CY2014Q4	neph	Class Of Warrant Or Right Issued Net Value Received ClassOfWarrantOrRightIssuedNetValueReceived	1100000	USD
CY2014Q1	neph	Repayments Of Accrued Interest On Senior Secured Note RepaymentsOfAccruedInterestOnSeniorSecuredNote	61000	USD
CY2013Q2	neph	Repayments Of Accrued Interest On Senior Secured Note RepaymentsOfAccruedInterestOnSeniorSecuredNote	46800	USD
CY2014Q4	neph	Repayments Of Accrued Interest On Senior Secured Note RepaymentsOfAccruedInterestOnSeniorSecuredNote	64000	USD
CY2014Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.30
CY2014Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.60
CY2012Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-8724000	USD
CY2013	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-2000	USD
CY2014	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-2000	USD
CY2013	neph	Stock Issued During Period Value Shareholder Rights Offering StockIssuedDuringPeriodValueShareholderRightsOffering	2771000	USD
CY2014	neph	Stock Issued During Period Value Shareholder Rights Offering StockIssuedDuringPeriodValueShareholderRightsOffering	4866000	USD
CY2013	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities Net Of Adjustments StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments	248000	USD
CY2014	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities Net Of Adjustments StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments	15000	USD
CY2014	us-gaap	Proceeds From Issuance Of Senior Long Term Debt ProceedsFromIssuanceOfSeniorLongTermDebt	1572000	USD
CY2014	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	3203000	USD
CY2013	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	652000	USD
CY2014	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	530000	USD
CY2013	us-gaap	Depreciation Depreciation	9000	USD
CY2014	us-gaap	Depreciation Depreciation	6000	USD
CY2013	us-gaap	Adjustment For Amortization AdjustmentForAmortization	214000	USD
CY2014	us-gaap	Adjustment For Amortization AdjustmentForAmortization	210000	USD
CY2013	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	575000	USD
CY2014	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	429000	USD
CY2013	neph	Noncash Warrant Inducement NoncashWarrantInducement	14000	USD
CY2014	neph	Noncash Warrant Inducement NoncashWarrantInducement	0	USD
CY2013	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	257000	USD
CY2014	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	320000	USD
CY2013	neph	Inventory Fifo Reserve Period Charge InventoryFifoReservePeriodCharge	210000	USD
CY2014	neph	Inventory Fifo Reserve Period Charge InventoryFifoReservePeriodCharge	59000	USD
CY2013	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-26000	USD
CY2013	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-820000	USD
CY2013	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	60000	USD
CY2013	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	16000	USD
CY2014	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-21000	USD
CY2013	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-23000	USD
CY2014	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-190000	USD
CY2013	neph	Increase Decrease In License And Supply Agreement Fee Payable IncreaseDecreaseInLicenseAndSupplyAgreementFeePayable	-1318000	USD
CY2013	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-711000	USD
CY2013	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-3583000	USD
CY2013	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	3000	USD
CY2013	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	3000	USD
CY2013	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	2771000	USD
CY2014	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	4866000	USD
CY2013	us-gaap	Proceeds From Issuance Of Senior Long Term Debt ProceedsFromIssuanceOfSeniorLongTermDebt	2800000	USD
CY2013	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	248000	USD
CY2014	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	15000	USD
CY2013	us-gaap	Repayments Of Senior Debt RepaymentsOfSeniorDebt	1300000	USD
CY2014	us-gaap	Repayments Of Senior Debt RepaymentsOfSeniorDebt	3250000	USD
CY2013	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	399000	USD
CY2014	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	0	USD
CY2013	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	4120000	USD
CY2013	us-gaap	Effect Of Exchange Rate On Cash EffectOfExchangeRateOnCash	-8000	USD
CY2014	us-gaap	Effect Of Exchange Rate On Cash EffectOfExchangeRateOnCash	-3000	USD
CY2013	us-gaap	Cash Period Increase Decrease CashPeriodIncreaseDecrease	532000	USD
CY2014	us-gaap	Cash Period Increase Decrease CashPeriodIncreaseDecrease	705000	USD
CY2013	us-gaap	Income Taxes Paid IncomeTaxesPaid	2000	USD
CY2014	us-gaap	Income Taxes Paid IncomeTaxesPaid	6000	USD
CY2013	us-gaap	Interest Paid InterestPaid	54000	USD
CY2014	us-gaap	Interest Paid InterestPaid	188000	USD
CY2013	neph	Restricted Stock Shares Issued To Settle Liability RestrictedStockSharesIssuedToSettleLiability	77000	USD
CY2014	neph	Restricted Stock Shares Issued To Settle Liability RestrictedStockSharesIssuedToSettleLiability	101000	USD
CY2013	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	229000	USD
CY2014	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	276000	USD
CY2014	us-gaap	Nature Of Operations NatureOfOperations	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="center"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Note 1 - Organization and Nature of Operations</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Nephros, Inc. (“Nephros” or the “Company”) was incorporated under the laws of the State of Delaware on April 3, 1997. Nephros was founded by health professionals, scientists and engineers affiliated with Columbia University to develop advanced End Stage Renal Disease (“ESRD”) therapy technology and products. The Company has two products in the hemodiafiltration, or HDF, modality to deliver therapy for ESRD patients. These are the OLpūr mid-dilution HDF filter or “dialyzer,” designed expressly for HDF therapy, and the OLpūr H2H HDF module, an add-on module designed to allow the most common types of hemodialysis machines to be used for HDF therapy. In 2009, the Company introduced its Dual Stage Ultrafilter (“DSU”) water filter, which represented a new and complementary product line to the Company’s ESRD therapy business. The DSU incorporates the Company’s unique and proprietary dual stage filter architecture.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">On June 4, 2003, Nephros International Limited was incorporated under the laws of Ireland as a wholly-owned subsidiary of the Company.  In August 2003, the Company established a European Customer Service and financial operations center in Dublin, Ireland.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The U.S. facilities, located at 41 Grand Avenue, River Edge, New Jersey, 07661, are used to house the Company’s corporate headquarters and research facilities.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2013	neph	Adjustments To Additional Paid In Capital Warrant Incremental Fair Value Of Inducement AdjustmentsToAdditionalPaidInCapitalWarrantIncrementalFairValueOfInducement	14000	USD
CY2013	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	0	USD
CY2014	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	0	USD
CY2013	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	3000	USD
CY2014	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	0	USD
CY2013Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	734000	USD
CY2014Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	734000	USD
CY2013Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	727000	USD
CY2014Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	733000	USD
CY2014	us-gaap	Property Plant And Equipment Impairment PropertyPlantAndEquipmentImpairment	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Impairment for Long-Lived Assets</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">The Company adheres to Accounting Standards Codification (“ASC”) Topic 360 and periodically evaluates whether current facts or circumstances indicate that the carrying value of its depreciable assets to be held and used may not</font> <font style="FONT-SIZE: 10pt">be recoverable. If such circumstances are determined to exist, an estimate of undiscounted future cash flows produced by the long-lived assets, or the appropriate grouping of assets, is compared to the carrying value to determine whether impairment exists. If an asset is determined to be impaired, the loss is measured based on the difference between the asset’s fair value and its carrying value. An estimate of the asset’s fair value is based on quoted market prices in active markets, if available. If quoted market prices are not available, the estimate of fair value is based on various valuation techniques, including a discounted value of estimated future cash flows. The Company reports an asset to be disposed of at the lower of its carrying value or its estimated net realizable market value. There were no impairment losses for long-lived assets recorded for the years ended December 31, 2014 and December 31, 2013.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2013Q2	neph	Class Of Warrant Or Right Issued Shares ClassOfWarrantOrRightIssuedShares	5000000	shares
CY2014Q4	neph	Class Of Warrant Or Right Issued Shares ClassOfWarrantOrRightIssuedShares	5000000	shares
CY2013Q2	us-gaap	Debt Instrument Fee Amount DebtInstrumentFeeAmount	104000	USD
CY2013Q2	neph	Reimbursement Of Legal Fee ReimbursementOfLegalFee	100000	USD
CY2014Q4	neph	Reimbursement Of Legal Fee ReimbursementOfLegalFee	75000	USD
CY2013Q2	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	204000	USD
CY2013	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	9000	USD
CY2014	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	6000	USD
CY2014	us-gaap	Defined Contribution Plan Maximum Annual Contributions Per Employee Percent DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent	0.15	pure
CY2013	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	46000	USD
CY2014	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	43000	USD
CY2013Q4	neph	Accrued Professional Fees Current Legal AccruedProfessionalFeesCurrentLegal	149000	USD
CY2014Q4	neph	Accrued Professional Fees Current Legal AccruedProfessionalFeesCurrentLegal	145000	USD
CY2013Q4	neph	Accrued Product Recall AccruedProductRecall	60000	USD
CY2014Q4	neph	Accrued Product Recall AccruedProductRecall	0	USD
CY2013Q4	neph	Accrued Compensation Current AccruedCompensationCurrent	0	USD
CY2014Q4	neph	Accrued Compensation Current AccruedCompensationCurrent	36000	USD
CY2013Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	81000	USD
CY2014Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	50000	USD
CY2013Q4	neph	Accrued Interest Current AccruedInterestCurrent	39000	USD
CY2014Q4	neph	Accrued Interest Current AccruedInterestCurrent	14000	USD
CY2013Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	36000	USD
CY2014Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	47000	USD
CY2013Q4	us-gaap	Deferred Revenue DeferredRevenue	703000	USD
CY2014Q4	us-gaap	Deferred Revenue DeferredRevenue	487000	USD
CY2014	us-gaap	Recognition Of Deferred Revenue RecognitionOfDeferredRevenue	487000	USD
CY2013	us-gaap	Shipping Handling And Transportation Costs ShippingHandlingAndTransportationCosts	5000	USD
CY2014	us-gaap	Shipping Handling And Transportation Costs ShippingHandlingAndTransportationCosts	4000	USD
CY2014Q4	us-gaap	Contractual Obligation ContractualObligation	281000	USD
CY2014Q4	us-gaap	Contractual Obligation Due In Next Twelve Months ContractualObligationDueInNextTwelveMonths	279000	USD
CY2014Q4	us-gaap	Contractual Obligation Due In Second And Third Year ContractualObligationDueInSecondAndThirdYear	2000	USD
CY2014Q4	us-gaap	Contractual Obligation Due In Fourth And Fifth Year ContractualObligationDueInFourthAndFifthYear	0	USD
CY2014Q4	us-gaap	Contractual Obligation Due After Fifth Year ContractualObligationDueAfterFifthYear	0	USD
CY2013	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.3500	pure
CY2014	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.3500	pure
CY2013	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0640	pure
CY2014	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0502	pure
CY2013	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.0200	pure
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.0020	pure
CY2013	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-0.0310	pure
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.0055	pure
CY2013	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	0.0650	pure
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	-0.0310	pure
CY2013	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	1.0830	pure
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.1397	pure
CY2013	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2014	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2013	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	399000	USD
CY2014	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	142000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	27029000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	27935165	USD
CY2013Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	1096000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	1118389	USD
CY2013Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1801000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1913673	USD
CY2013Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	408000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	436178	USD
CY2013Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	30334000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	31403405	USD
CY2013	neph	Other Income Adjustments To Liabilities And Foreign Currency Losses OtherIncomeAdjustmentsToLiabilitiesAndForeignCurrencyLosses	36000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	30334000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	31403405	USD
CY2013Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2014Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2013	us-gaap	Interest And Other Income InterestAndOtherIncome	17000	USD
CY2014Q4	us-gaap	Accumulated Amortization Of Other Deferred Costs AccumulatedAmortizationOfOtherDeferredCosts	566000	USD
CY2013	us-gaap	Other Amortization Of Deferred Charges OtherAmortizationOfDeferredCharges	214000	USD
CY2014	us-gaap	Other Amortization Of Deferred Charges OtherAmortizationOfDeferredCharges	210000	USD
CY2014Q4	neph	Finite Lived Intangible Assets Amortization Expense Years Two And Three FiniteLivedIntangibleAssetsAmortizationExpenseYearsTwoAndThree	210000	USD
CY2014	neph	Royalty Rate RoyaltyRate	0.03	pure
CY2013Q4	neph	Operating Lease Monthly Rent Expense OperatingLeaseMonthlyRentExpense	8000	USD
CY2013Q4	us-gaap	Prepaid Insurance PrepaidInsurance	70000	USD
CY2014Q4	us-gaap	Prepaid Insurance PrepaidInsurance	70000	USD
CY2013Q4	us-gaap	Deposits Assets Current DepositsAssetsCurrent	21000	USD
CY2014Q4	us-gaap	Deposits Assets Current DepositsAssetsCurrent	21000	USD
CY2013Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	34000	USD
CY2014Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	13000	USD
CY2013Q4	us-gaap	Other Assets Current OtherAssetsCurrent	125000	USD
CY2014Q4	us-gaap	Other Assets Current OtherAssetsCurrent	104000	USD
CY2014	neph	Number Of Products In Development NumberOfProductsInDevelopment	2	pure
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.298	pure
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.298	pure
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0136	pure
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0186	pure
CY2013	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y10M28D
CY2014	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y10M2D
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2014Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	2472234	shares
CY2014Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1	0.96
CY2014Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions	1679392	shares
CY2014Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1	1.11
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2294714	shares
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	237315	shares
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	352519	shares
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	121895	shares
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	290419	shares
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2410134	shares
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2472234	shares
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1679392	shares
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	2426249	shares
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.14
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.28
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.96
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	1.11
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	1.04
CY2013Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	5081023	shares
CY2014Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	5010815	shares
CY2013	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	418000	USD
CY2014	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	421000	USD
CY2013	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	519000	USD
CY2014	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	507000	USD
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.56
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.45
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	USD
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	241000	USD
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	0	USD
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	235000	USD
CY2013	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P8Y1M6D
CY2014	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P7Y6M
CY2014Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	504000	USD
CY2014	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y10M24D
CY2013Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.45
CY2014Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.33
CY2013	neph	Warrants Exercised WarrantsExercised	2254500	shares
CY2014	neph	Warrants Exercised WarrantsExercised	791278	shares
CY2014	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	36570	shares
CY2014Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions	8000	USD
CY2013	neph	Additional Shares Not Issued Results Of Warrants Exercised AdditionalSharesNotIssuedResultsOfWarrantsExercised	374	shares
CY2014	dei	Document Type DocumentType	10-K
CY2014	dei	Amendment Flag AmendmentFlag	false
CY2014	dei	Document Period End Date DocumentPeriodEndDate	2014-12-31
CY2014	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2014
CY2014	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2014	dei	Entity Registrant Name EntityRegistrantName	NEPHROS INC
CY2014	dei	Entity Central Index Key EntityCentralIndexKey	0001196298
CY2014	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2014	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2014	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2013	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	116000	USD
CY2014	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	117000	USD
CY2014Q3	neph	Operating Lease Monthly Rent Expense Renewal Amount OperatingLeaseMonthlyRentExpenseRenewalAmount	8800	USD
CY2014	neph	Lease Extension Term LeaseExtensionTerm	P6M
CY2013	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.64
CY2014	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.50
CY2014	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2014	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
CY2014Q2	dei	Entity Public Float EntityPublicFloat	15004000	USD
CY2014	dei	Trading Symbol TradingSymbol	NEPH
CY2013Q3	neph	Lease Extension Term LeaseExtensionTerm	P1Y
CY2014Q1	us-gaap	Repayments Of Senior Debt RepaymentsOfSeniorDebt	1500000	USD
CY2013Q2	us-gaap	Repayments Of Senior Debt RepaymentsOfSeniorDebt	1300000	USD
CY2014Q4	us-gaap	Repayments Of Senior Debt RepaymentsOfSeniorDebt	1750000	USD
CY2013Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	USD
CY2014Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	1000	USD
CY2015Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	30393640	shares
CY2013	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	0	USD
CY2014	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	0	USD
CY2013	us-gaap	Sales Returns And Allowances Goods SalesReturnsAndAllowancesGoods	0	USD
CY2014	us-gaap	Sales Returns And Allowances Goods SalesReturnsAndAllowancesGoods	0	USD
CY2014	us-gaap	Interest Expense Debt InterestExpenseDebt	178000	USD
CY2014Q4	neph	Accrued Sec Reporting Current AccruedSecReportingCurrent	27000	USD
CY2014Q4	neph	Accrued Accounting Current AccruedAccountingCurrent	23000	USD
CY2013	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	3.27
CY2014	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	2.45
CY2014Q1	neph	Subscription Rights Percentage SubscriptionRightsPercentage	0.77	pure
CY2014Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	7140823	shares
CY2014Q1	us-gaap	Legal Fees LegalFees	128000	USD
CY2013	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.18
CY2014	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.31
CY2013	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	20760410	shares
CY2014	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	23817184	shares
CY2013	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-5020000	USD
CY2014	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	4277000	USD
CY2013	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	121000	USD
CY2014	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	78000	USD
CY2009Q1	neph	Warrant Liability WarrantLiability	2107000	USD
CY2013Q1	neph	Warrant Liability WarrantLiability	5372000	USD
CY2014Q1	neph	Warrant Liability WarrantLiability	5859000	USD
CY2013Q2	neph	Warrant Liability WarrantLiability	5980000	USD
CY2014Q2	neph	Warrant Liability WarrantLiability	10544000	USD
CY2013Q3	neph	Warrant Liability WarrantLiability	7776000	USD
CY2014Q3	neph	Warrant Liability WarrantLiability	7116000	USD
CY2009Q4	neph	Warrant Liability WarrantLiability	6272000	USD
CY2010Q4	neph	Warrant Liability WarrantLiability	458000	USD
CY2011Q4	neph	Warrant Liability WarrantLiability	5096000	USD
CY2012Q4	neph	Warrant Liability WarrantLiability	8129000	USD
CY2013Q4	neph	Warrant Liability WarrantLiability	3109000	USD
CY2009Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	86612000	USD
CY2013Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	99445000	USD
CY2014Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	105114000	USD
CY2013Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	102648000	USD
CY2014Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	105219000	USD
CY2013Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	102848000	USD
CY2014Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	105322000	USD
CY2009Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	93944000	USD
	neph	Increase Decrease In Warrant Liability IncreaseDecreaseInWarrantLiability	352000	USD
CY2012	neph	Increase Decrease In Warrant Liability IncreaseDecreaseInWarrantLiability	-3361000	USD
CY2013Q1	neph	Increase Decrease In Warrant Liability IncreaseDecreaseInWarrantLiability	2756000	USD
	neph	Increase Decrease In Warrant Liability IncreaseDecreaseInWarrantLiability	2149000	USD
CY2010Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	94108000	USD
CY2011Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	97759000	USD
CY2012Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	99304000	USD
CY2009Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-86293000	USD
CY2013Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-106602000	USD
CY2014Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-110305000	USD
CY2013Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-107879000	USD
CY2014Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-115644000	USD
CY2013Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-110287000	USD
CY2014Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-112921000	USD
CY2009Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-98375000	USD
CY2010Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-94495000	USD
CY2011Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-101493000	USD
CY2012Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-108116000	USD
CY2010	neph	Increase Decrease In Warrant Liability IncreaseDecreaseInWarrantLiability	5813000	USD
CY2011	neph	Increase Decrease In Warrant Liability IncreaseDecreaseInWarrantLiability	-4638000	USD
CY2014Q1	neph	Increase Decrease In Warrant Liability IncreaseDecreaseInWarrantLiability	-2751000	USD
	neph	Increase Decrease In Warrant Liability IncreaseDecreaseInWarrantLiability	-7436000	USD
	neph	Increase Decrease In Warrant Liability IncreaseDecreaseInWarrantLiability	-4007000	USD
CY2009	neph	Increase Decrease In Warrant Liability IncreaseDecreaseInWarrantLiability	-10056000	USD
CY2013Q2	neph	Increase Decrease In Warrant Liability IncreaseDecreaseInWarrantLiability	-608000	USD
CY2014Q2	neph	Increase Decrease In Warrant Liability IncreaseDecreaseInWarrantLiability	-4685000	USD
CY2013Q3	neph	Increase Decrease In Warrant Liability IncreaseDecreaseInWarrantLiability	-1797000	USD
CY2014Q3	neph	Increase Decrease In Warrant Liability IncreaseDecreaseInWarrantLiability	3428000	USD
CY2010	us-gaap	Net Income Loss NetIncomeLoss	3880000	USD
CY2011	us-gaap	Net Income Loss NetIncomeLoss	-6998000	USD
CY2012	us-gaap	Net Income Loss NetIncomeLoss	-6623000	USD
CY2013Q1	us-gaap	Net Income Loss NetIncomeLoss	1514000	USD
	us-gaap	Net Income Loss NetIncomeLoss	237000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-2171000	USD
CY2014Q1	us-gaap	Net Income Loss NetIncomeLoss	-3511000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-8850000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-6127000	USD
CY2009	us-gaap	Net Income Loss NetIncomeLoss	-12082000	USD
CY2013Q2	us-gaap	Net Income Loss NetIncomeLoss	-1279000	USD
CY2014Q2	us-gaap	Net Income Loss NetIncomeLoss	-5339000	USD
CY2013Q3	us-gaap	Net Income Loss NetIncomeLoss	-2408000	USD
CY2014Q3	us-gaap	Net Income Loss NetIncomeLoss	2723000	USD
CY2010	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	1.86
CY2011	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.81
CY2012	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.59
CY2013Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.07
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.15
CY2013	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.18
CY2014Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.19
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.40
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.27
CY2009	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-6.32
CY2013Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.10
CY2014Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.21
CY2013Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.14
CY2013Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	17633360	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	19706210	shares
CY2013	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	20760410	shares
CY2014Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	33491189	shares
CY2011	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-6971000	USD
CY2012	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-6596000	USD
CY2013Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	1514000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	235000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-2173000	USD
CY2014Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3512000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-8852000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-6128000	USD
CY2013Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1281000	USD
CY2014Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-5340000	USD
CY2013Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-2408000	USD
CY2014Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	2724000	USD
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1385199	shares
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	2350688	shares
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	1.46
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	1.29
CY2014Q4	neph	Warrant Liability WarrantLiability	7386000	USD
CY2014	neph	Increase Decrease In Warrant Liability IncreaseDecreaseInWarrantLiability	4277000	USD
CY2013	neph	Increase Decrease In Warrant Liability IncreaseDecreaseInWarrantLiability	-5020000	USD
CY2012Q4	us-gaap	Cash Cash	47000	USD
CY2014Q4	us-gaap	Liabilities Fair Value Disclosure Recurring LiabilitiesFairValueDisclosureRecurring	7386000	USD
CY2013Q4	us-gaap	Liabilities Fair Value Disclosure Recurring LiabilitiesFairValueDisclosureRecurring	3109000	USD
CY2014	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <b>Concentration of Credit Risk</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Company deposits its cash in financial institutions. At times, such deposits may be in excess of insured limits. To date, the Company has not experienced any impairment losses on its cash.</div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2014	neph	Fair Value Of Calculated Aggregate Value FairValueOfCalculatedAggregateValue	7386000	USD
CY2013	neph	Fair Value Of Calculated Aggregate Value FairValueOfCalculatedAggregateValue	3109000	USD
CY2014	neph	Weighted Average Exercise Price Fair Value WeightedAverageExercisePriceFairValue	0.30
CY2013	neph	Weighted Average Exercise Price Fair Value WeightedAverageExercisePriceFairValue	0.40
CY2014	neph	Closing Price Per Share Of Common Stock Fair Value ClosingPricePerShareOfCommonStockFairValue	0.79
CY2013	neph	Closing Price Per Share Of Common Stock Fair Value ClosingPricePerShareOfCommonStockFairValue	0.42
CY2014	us-gaap	Fair Value Assumptions Expected Volatility Rate FairValueAssumptionsExpectedVolatilityRate	1.656	pure
CY2013	us-gaap	Fair Value Assumptions Expected Volatility Rate FairValueAssumptionsExpectedVolatilityRate	1.035	pure
CY2014	us-gaap	Fair Value Assumptions Expected Term FairValueAssumptionsExpectedTerm	P5Y2M12D
CY2013	us-gaap	Fair Value Assumptions Expected Term FairValueAssumptionsExpectedTerm	P5Y
CY2014	us-gaap	Fair Value Assumptions Risk Free Interest Rate FairValueAssumptionsRiskFreeInterestRate	0.018	pure
CY2013	us-gaap	Fair Value Assumptions Risk Free Interest Rate FairValueAssumptionsRiskFreeInterestRate	0.016	pure
CY2014	us-gaap	Fair Value Assumptions Expected Dividend Rate FairValueAssumptionsExpectedDividendRate	0	pure
CY2013	us-gaap	Fair Value Assumptions Expected Dividend Rate FairValueAssumptionsExpectedDividendRate	0	pure
CY2014	us-gaap	Interest Expense Lessee Assets Under Capital Lease InterestExpenseLesseeAssetsUnderCapitalLease	500	EUR
CY2014	us-gaap	Interest Expense Lessee Assets Under Capital Lease InterestExpenseLesseeAssetsUnderCapitalLease	600	USD
CY2014	neph	Notice Period On Lease Agreement NoticePeriodOnLeaseAgreement	P2M
CY2014Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.02
CY2014Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.11
CY2013Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.13
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.02
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.10
CY2014Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	2723000	USD
CY2013	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	1322000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	237000	USD
CY2014Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	25238412	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	14556050	shares
CY2014Q3	us-gaap	Dilutive Securities DilutiveSecurities	-3429000	USD
CY2013	us-gaap	Dilutive Securities DilutiveSecurities	-5020000	USD
	us-gaap	Dilutive Securities DilutiveSecurities	-2149000	USD
CY2014Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-706000	USD
CY2013	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-3698000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-1912000	USD
CY2014Q3	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	8252777	shares
CY2013	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	5135411	shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	5150160	shares
CY2014Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	33491189	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	19706210	shares
CY2013Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	1514000	USD
CY2010	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	3880000	USD
CY2013Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	12009285	shares
CY2010	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2087068	shares
CY2010	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.86
CY2013Q1	us-gaap	Dilutive Securities DilutiveSecurities	-2756000	USD
CY2010	us-gaap	Dilutive Securities DilutiveSecurities	0	USD
CY2013Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-1242000	USD
CY2010	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	3880000	USD
CY2013Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	5624075	shares
CY2010	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
CY2013Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	17633360	shares
CY2010	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	2087068	shares
CY2013Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.07
CY2010	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.86
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Deductions Other EffectiveIncomeTaxRateReconciliationDeductionsOther	-0.2370	pure
CY2013	us-gaap	Effective Income Tax Rate Reconciliation Deductions Other EffectiveIncomeTaxRateReconciliationDeductionsOther	-1.5510	pure

Files In Submission

Name	View Source	Status
0001144204-15-022858-index-headers.html	Edgar Link	pending
0001144204-15-022858-index.html	Edgar Link	pending
0001144204-15-022858.txt	Edgar Link	pending
0001144204-15-022858-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
neph-20141231.xml	Edgar Link	completed
neph-20141231.xsd	Edgar Link	pending
neph-20141231_cal.xml	Edgar Link	unprocessable
neph-20141231_def.xml	Edgar Link	unprocessable
neph-20141231_lab.xml	Edgar Link	unprocessable
neph-20141231_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v399849_10k.htm	Edgar Link	pending
v399849_ex23-1.htm	Edgar Link	pending
v399849_ex23-2.htm	Edgar Link	pending
v399849_ex31-1.htm	Edgar Link	pending
v399849_ex32-1.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NEPH
NEPHROS INC Stock $neph

2014 Q4 Form 10-K Financial Statement

#000114420415022858 Filed on April 15, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NEPH NEPHROS INC Stock $neph

2014 Q4 Form 10-K Financial Statement

#000114420415022858 Filed on April 15, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NEPH
NEPHROS INC Stock $neph